Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer (scientific article (publication date: 2010))

cites work (P2860)

Q57134612	Q57134612
Q34506546	A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer
Q36200972	A Long-Lived Luminal Subpopulation Enriched with Alveolar Progenitors Serves as Cellular Origin of Heterogeneous Mammary Tumors
Q30665904	A Molecular Toolkit to Visualize Native Protein Assemblies in the Context of Human Disease
Q38720232	A New Role for ERα: Silencing via DNA Methylation of Basal, Stem Cell, and EMT Genes
Q64085234	A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
Q26752846	A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer
Q89863761	A SUMOylation-dependent HIF-1α/CLDN6 negative feedback mitigates hypoxia-induced breast cancer metastasis
Q35685928	A block in lineage differentiation of immortal human mammary stem / progenitor cells by ectopically-expressed oncogenes
Q47113193	A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib.
Q34365829	A central role for TRPS1 in the control of cell cycle and cancer development
Q52657794	A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification.
Q35106947	A core invasiveness gene signature reflects epithelial-to-mesenchymal transition but not metastatic potential in breast cancer cell lines and tissue samples
Q47099062	A double-negative feedback loop between EpCAM and ERK contributes to the regulation of epithelial-mesenchymal transition in cancer
Q94671670	A dual role of Irf1 in maintaining epithelial identity but also enabling EMT and metastasis formation of breast cancer cells
Q39436586	A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer
Q37171616	A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells
Q33835581	A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer
Q39675117	A high capacity polymeric micelle of paclitaxel: Implication of high dose drug therapy to safety and in vivo anti-cancer activity
Q64916373	A high-risk luminal A dominant breast cancer subtype with increased mobility.
Q38720911	A landscape of synthetic viable interactions in cancer.
Q35750639	A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer
Q53172822	A mouse model with T58A mutations in Myc reduces the dependence on KRas mutations and has similarities to claudin-low human breast cancer.
Q34646243	A network module-based method for identifying cancer prognostic signatures
Q36664694	A new genome-driven integrated classification of breast cancer and its implications
Q37706944	A novel ZEB1/HAS2 positive feedback loop promotes EMT in breast cancer
Q61798221	A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses
Q35796943	A novel embryonic plasticity gene signature that predicts metastatic competence and clinical outcome.
Q39035017	A novel non-parametric method for uncertainty evaluation of correlation-based molecular signatures: its application on PAM50 algorithm.
Q48118338	A novel patient-derived xenograft model for claudin-low triple-negative breast cancer.
Q33807643	A personalized committee classification approach to improving prediction of breast cancer metastasis
Q28307891	A perspective on cancer cell metastasis
Q30422919	A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.
Q37008808	A quantitative atlas of histone modification signatures from human cancer cells
Q35838290	A refined molecular taxonomy of breast cancer
Q37067545	A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models
Q89475542	A role for CBFβ in maintaining the metastatic phenotype of breast cancer cells
Q92782388	A role for kinesin-1 subunits KIF5B/KLC1 in regulating epithelial mesenchymal plasticity in breast tumorigenesis
Q34372200	A stem cell medium containing neural stimulating factor induces a pancreatic cancer stem-like cell-enriched population
Q38708251	A stemness-related ZEB1-MSRB3 axis governs cellular pliancy and breast cancer genome stability.
Q35886083	A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer
Q35769036	A three-gene model to robustly identify breast cancer molecular subtypes
Q34252280	ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells.
Q35155403	ADAM12-L is a direct target of the miR-29 and miR-200 families in breast cancer
Q35889585	ARTEMIN synergizes with TWIST1 to promote metastasis and poor survival outcome in patients with ER negative mammary carcinoma
Q37023688	ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
Q36545548	Aberrant high expression of immunoglobulin G in epithelial stem/progenitor-like cells contributes to tumor initiation and metastasis.
Q38418048	Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells
Q33875120	Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer
Q37356654	Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines
Q33608593	Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes
Q53788180	Addition of vasopressin synthetic analogue [V(4)Q(5)]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models.
Q38046581	Adjuvant treatments for triple-negative breast cancers
Q36935007	Age-associated gene expression in normal breast tissue mirrors qualitative age-at-incidence patterns for breast cancer.
Q33750880	Age-associated prognostic and predictive biomarkers in patients with breast cancer
Q34359310	Age-specific changes in intrinsic breast cancer subtypes: a focus on older women
Q46500752	Alcohol promotes migration and invasion of triple-negative breast cancer cells through activation of p38 MAPK and JNK.
Q54157077	Altered Circadian Rhythms and Breast Cancer: From the Human to the Molecular Level
Q38830526	Altered purinergic receptor-Ca²⁺ signaling associated with hypoxia-induced epithelial-mesenchymal transition in breast cancer cells
Q35014541	Alternative mRNA splicing generates two distinct ADAM12 prodomain variants.
Q36187733	An "elite hacker": breast tumors exploit the normal microenvironment program to instruct their progression and biological diversity
Q57825986	An Effect of Culture Media on Epithelial Differentiation Markers in Breast Cancer Cell Lines MCF7, MDA-MB-436 and SkBr3
Q33355327	An Integrative Genomics Approach for Associating GWAS Information with Triple-Negative Breast Cancer.
Q57106403	An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers
Q58599063	An assessment of prognostic immunity markers in breast cancer
Q30654061	An epigenetically distinct breast cancer cell subpopulation promotes collective invasion
Q38824148	An epithelial to mesenchymal transition programme does not usually drive the phenotype of invasive lobular carcinomas.
Q36315707	An essential role of metalloprotease-disintegrin ADAM12 in triple-negative breast cancer
Q33828295	An in vitro model that recapitulates the epithelial to mesenchymal transition (EMT) in human breast cancer
Q34778702	Analysis and prediction of pathways in HeLa cells by integrating biological levels of organization with systems-biology approaches
Q41684904	Analysis of Contractility and Invasion Potential of Two Canine Mammary Tumor Cell Lines.
Q28603678	Analysis of the miRNA-mRNA-lncRNA networks in ER+ and ER- breast cancer cell lines
Q35651216	Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients
Q42505007	Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells
Q36781090	Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties
Q36791878	Antibody Therapeutics in Oncology
Q38745095	Applying Multivariate Adaptive Splines to Identify Genes With Expressions Varying After Diagnosis in Microarray Experiments
Q42748172	Appraisal of progenitor markers in the context of molecular classification of breast cancers
Q26744054	Approach to the Triple Negative Breast Cancer in New Drugs Area
Q36466583	Artemin stimulates radio- and chemo-resistance by promoting TWIST1-BCL-2-dependent cancer stem cell-like behavior in mammary carcinoma cells
Q64069774	Assessing metastatic potential of breast cancer cells based on EGFR dynamics
Q52655168	Assessment of CXC ligand 12-mediated calcium signalling and its regulators in basal-like breast cancer cells.
Q34805496	Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization
Q42442457	Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection.
Q64059416	Associating expression and genomic data using co-occurrence measures
Q91894537	Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer
Q64087952	Association of FOSL1 copy number alteration and triple negative breast tumors
Q30000323	Association of Protein Translation and Extracellular Matrix Gene Sets with Breast Cancer Metastasis: Findings Uncovered on Analysis of Multiple Publicly Available Datasets Using Individual Patient Data Approach
Q37400131	Asymmetric segregation of template DNA strands in basal-like human breast cancer cell lines
Q37107334	Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers
Q57059036	Aurantoside C Targets and Induces Apoptosis in Triple Negative Breast Cancer Cells
Q35050162	Autocrine CSF1R signaling mediates switching between invasion and proliferation downstream of TGFβ in claudin-low breast tumor cells
Q38205233	Axes of differentiation in breast cancer: untangling stemness, lineage identity, and the epithelial to mesenchymal transition.
Q52578595	BCDForest: a boosting cascade deep forest model towards the classification of cancer subtypes based on gene expression data.
Q35114304	BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells
Q35368266	BRCA1 Alternative splicing landscape in breast tissue samples.
Q33798713	BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells
Q37994602	BRCA1--conductor of the breast stem cell orchestra: the role of BRCA1 in mammary gland development and identification of cell of origin of BRCA1 mutant breast cancer
Q35931900	Basal breast cancer: a complex and deadly molecular subtype
Q37853555	Basal phenotype breast cancer: implications for treatment and prognosis
Q89011293	Basal-like Breast Cancers: From Pathology to Biology and Back Again
Q36070080	Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival
Q36618624	Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Q92236253	Bayesian Neural Networks for Selection of Drug Sensitive Genes
Q55435354	Benzylserine inhibits breast cancer cell growth by disrupting intracellular amino acid homeostasis and triggering amino acid response pathways.
Q35922960	Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells
Q35073921	Biologic markers determine both the risk and the timing of recurrence in breast cancer
Q98771182	Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4
Q36460884	Biological role of NK cells and immunotherapeutic approaches in breast cancer
Q38893074	Biology and Management of Patients With Triple-Negative Breast Cancer
Q35791606	Breast Cancer Cell Line Aggregate Morphology Does Not Predict Invasive Capacity
Q92916959	Breast Cancer Heterogeneity in Primary and Metastatic Disease
Q57105168	Breast Cancer Heterogeneity: A focus on Epigenetics and In Vitro 3D Model Systems
Q90632786	Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments
Q50094810	Breast Cancer: Multiple Subtypes within a Tumor?
Q30245184	Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications
Q57112840	Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis
Q26851620	Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity
Q42473382	Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights
Q34372180	Breast cancer in European Union: an update of screening programmes as of March 2014 (review)
Q28076805	Breast cancer molecular subtypes: from TNBC to QNBC
Q38765793	Breast cancer stem cells programs: enter the (non)-code.
Q37564312	Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts
Q36040448	Breast cancer subtype predictors revisited: from consensus to concordance?
Q35501726	Breast cancer subtype-specific interactions with the microenvironment dictate mechanisms of invasion
Q34570193	Breast cancer subtyping from plasma proteins
Q33611408	Breast tumor specific mutation in GATA3 affects physiological mechanisms regulating transcription factor turnover
Q34769289	C-Terminal Binding Protein: A Molecular Link between Metabolic Imbalance and Epigenetic Regulation in Breast Cancer
Q91826800	C/EBPδ links IL-6 and HIF-1 signaling to promote breast cancer stem cell-associated phenotypes
Q91198651	CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer
Q34786582	CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression
Q35892362	CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer.
Q36204016	Cadherin cell adhesion system in canine mammary cancer: a review
Q27025564	Calcium influx pathways in breast cancer: opportunities for pharmacological intervention
Q36605526	Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies?
Q26743510	Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes
Q26781783	Cancer classification in the genomic era: five contemporary problems
Q36544839	Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas
Q58798774	Canonical PRC2 function is essential for mammary gland development and affects chromatin compaction in mammary organoids
Q35586803	Canonical and non-canonical NF-κB signaling promotes breast cancer tumor-initiating cells
Q43378663	Cat Mammary Tumors: Genetic Models for the Human Counterpart
Q35834041	Caveolin-1 expression is elevated in claudin-low mammary tumor cells
Q36823886	Cell Fate Decisions During Breast Cancer Development
Q64252693	Cell Reprogramming in Tumorigenesis and Its Therapeutic Implications for Breast Cancer
Q39014552	Cell lineage determinants as regulators of breast cancer metastasis
Q33767473	Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity
Q35832288	Cell type of origin as well as genetic alterations contribute to breast cancer phenotypes
Q33730172	Cell-state transitions regulated by SLUG are critical for tissue regeneration and tumor initiation
Q29619557	Cells of origin in cancer
Q27027468	Cellular reprogramming in skin cancer
Q45233639	Challenges translating breast cancer gene signatures into the clinic
Q33864348	Challenging the roles of CD44 and lipolysis stimulated lipoprotein receptor in conveying Clostridium perfringens iota toxin cytotoxicity in breast cancer
Q35620290	Changes in glycoprotein expression between primary breast tumour and synchronous lymph node metastases or asynchronous distant metastases
Q37321751	Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Q35608671	Choosing the right cell line for breast cancer research
Q37113161	Cigarette smoke induces epithelial to mesenchymal transition and increases the metastatic ability of breast cancer cells
Q91596428	Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
Q38633504	Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions
Q36893886	Cisplatin induces differentiation of breast cancer cells
Q26774988	Claudin 1 in Breast Cancer: New Insights
Q37725542	Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype
Q38394007	Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences
Q39631925	Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes.
Q36202958	Claudin-5 is involved in breast cancer cell motility through the N-WASP and ROCK signalling pathways.
Q36237815	Claudin-Low Breast Cancer; Clinical & Pathological Characteristics
Q41160701	Claudin-low bladder tumors are immune infiltrated and actively immune suppressed
Q34339847	Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization
Q92318039	Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers
Q55362310	Claudin3 is localized outside the tight junctions in human carcinomas.
Q39551561	Claudins and cancer stem cells
Q38953546	Claudins in cancer: bench to bedside
Q37278408	Clinical implications for loss or diminution of expression of Raf-1 kinase inhibitory protein and its phosphorylated form in ductal breast cancer
Q36271396	Clinical implications of molecular heterogeneity in triple negative breast cancer.
Q26800996	Clinical implications of the intrinsic molecular subtypes of breast cancer
Q84705036	Clinical importance of phosphatase of regenerating liver-3 expression in breast cancer
Q38431284	Clinical management of breast cancer heterogeneity
Q34147910	Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways
Q38754717	Clinical utility of gene-expression signatures in early stage breast cancer
Q36997687	Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers
Q37717271	Clinicopathologic features of triple negative breast cancers: an experience from Pakistan.
Q33855396	Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study
Q37255596	Co-evolution of breast-to-brain metastasis and neural progenitor cells
Q36256977	Combination Twist1 and CA15-3 in axillary lymph nodes for breast cancer prognosis
Q92858970	Combinatorial drug screening of mammary cells with induced mesenchymal transformation to identify drug combinations for triple-negative breast cancer
Q37024819	Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models
Q36918202	Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer
Q34880928	Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K
Q42290131	Common cytotoxic chemotherapeutics induce epithelial-mesenchymal transition (EMT) downstream of ER stress.
Q98771930	Comparative Analysis of the Development of Acquired Radioresistance in Canine and Human Mammary Cancer Cell Lines
Q35779268	Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells
Q36268076	Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver.
Q38006770	Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT).
Q89717498	Comprehensive Proteomic Characterization Reveals Subclass-Specific Molecular Aberrations within Triple-negative Breast Cancer
Q97538334	Comprehensive characterization of claudin-low breast tumors reflects the impact of the cell-of-origin on cancer evolution
Q35185688	Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer
Q24630844	Comprehensive molecular portraits of human breast tumours
Q34427267	Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut.
Q50505471	Connexins, E-cadherin, Claudin-7 and β-catenin transiently form junctional nexuses during the post-natal mammary gland development.
Q36148711	Consensus Analysis of Whole Transcriptome Profiles from Two Breast Cancer Patient Cohorts Reveals Long Non-Coding RNAs Associated with Intrinsic Subtype and the Tumour Microenvironment
Q38810340	Context-Specific Effects of TGF-β/SMAD3 in Cancer Are Modulated by the Epigenome.
Q60909030	Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells
Q33871555	Context-specific gene regulatory networks subdivide intrinsic subtypes of breast cancer
Q96642228	Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions
Q91013857	Controversies around epithelial-mesenchymal plasticity in cancer metastasis
Q34485060	Cooperativity of Rb, Brca1, and p53 in malignant breast cancer evolution
Q57908393	Coregulation of alternative splicing by hnRNPM and ESRP1 during EMT
Q34828696	Correlation analysis connects cancer subtypes
Q34482866	Correlations of differentially expressed gap junction connexins Cx26, Cx30, Cx32, Cx43 and Cx46 with breast cancer progression and prognosis
Q51357931	Correlative Light-Electron Microscopy Shows RGD-Targeted ZnO Nanoparticles Dissolve in the Intracellular Environment of Triple Negative Breast Cancer Cells and Cause Apoptosis with Intratumor Heterogeneity.
Q35064727	CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer
Q50117674	Crambescidin 800, Isolated from the Marine Sponge Monanchora viridis, Induces Cell Cycle Arrest and Apoptosis in Triple-Negative Breast Cancer Cells
Q37151653	Critical role of the WASF3 gene in JAK2/STAT3 regulation of cancer cell motility
Q35816299	Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer
Q34034112	Cyclin D1, Id1 and EMT in breast cancer
Q55409038	Cytokeratin 5/6 and cytokeratin 8/18 expression in triple negative breast cancers: clinicopathologic significance in South-Asian population.
Q34117601	DEAD-box helicase DP103 defines metastatic potential of human breast cancers
Q57790453	DNA Methylation Predicts the Response of Triple-Negative Breast Cancers to All-Trans Retinoic Acid
Q60310878	DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer
Q34154147	Deconstructing the molecular portraits of breast cancer
Q27012820	Deconvoluting the obesity and breast cancer link: secretome, soil and seed interactions
Q39433444	Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis
Q35586697	Defining breast cancer intrinsic subtypes by quantitative receptor expression
Q35778960	Defining the cellular precursors to human breast cancer
Q35865777	Defining the expressed breast cancer kinome
Q28482309	Derivation of myoepithelial progenitor cells from bipotent mammary stem/progenitor cells
Q37715569	Detecting gene signature activation in breast cancer in an absolute, single-patient manner
Q26766266	Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer
Q37293711	Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models
Q42443445	Difference in therapeutic response between basal and nonbasal triple-negative breast cancers.
Q64099045	Differential Expression of HSP90 in MDA-MB-231 and MCF-7 Cell Lines after Treatment with Doxorubicin
Q47093634	Differential response to exercise in claudin-low breast cancer
Q37269261	Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes
Q35025741	Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models.
Q58719654	Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer
Q37154506	Distinct FAK activities determine progenitor and mammary stem cell characteristics
Q34616600	Distinct luminal-type mammary carcinomas arise from orthotopic Trp53-null mammary transplantation of juvenile versus adult mice
Q38632844	Dogs as a Model for Cancer.
Q34136905	Dormant but migratory tumour cells in desmoplastic stroma of invasive ductal carcinomas.
Q35666010	Down Regulation of CLDND1 Induces Apoptosis in Breast Cancer Cells
Q47098442	Down-regulation of traditional oncomiRs in plasma of breast cancer patients.
Q97524417	Downregulated CDH3 decreases proliferation, migration, and invasion in thyroid cancer
Q58721369	Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation
Q34558758	Dual roles for immune metagenes in breast cancer prognosis and therapy prediction
Q35842503	Dynamics of MBD2 deposition across methylated DNA regions during malignant transformation of human mammary epithelial cells
Q42444996	Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation
Q64089216	EGCG-Derivative G28 Shows High Efficacy Inhibiting the Mammosphere-Forming Capacity of Sensitive and Resistant TNBC Models
Q34539617	ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer.
Q34288822	EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice.
Q55151345	EMT programs promote basal mammary stem cell and tumor-initiating cell stemness by inducing primary ciliogenesis and Hedgehog signaling.
Q58695604	EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
Q33739387	ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR
Q39276857	EZH2 promotes a bi-lineage identity in basal-like breast cancer cells.
Q90230389	Early Steps of Mammary Stem Cell Transformation by Exogenous Signals; Effects of Bisphenol Endocrine Disrupting Chemicals and Bone Morphogenetic Proteins
Q55001709	Effect of miR-146a-5p on proliferation and metastasis of triple-negative breast cancer via regulation of SOX5.
Q36047366	Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models
Q35640263	Elevated PI3K signaling drives multiple breast cancer subtypes
Q36903307	Elf5 - breast cancer's little helper
Q36903234	Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers
Q35485571	Emerging drug discovery approaches for selective targeting of "precursor" metastatic breast cancer cells: highlights and perspectives
Q26851833	Emerging role of cell polarity proteins in breast cancer progression and metastasis
Q26799622	Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer
Q37225107	Emerging roles of claudins in human cancer
Q24621116	Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts
Q64894187	Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma.
Q37480166	Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis.
Q47732435	Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer
Q48863076	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex
Q36689065	EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low
Q27011535	Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry
Q36286662	Epigenetic mechanisms in commonly occurring cancers.
Q39439645	Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties
Q36145725	Epithelial-Mesenchymal Transition Phenotype Is Associated with Clinicopathological Factors That Indicate Aggressive Biological Behavior and Poor Clinical Outcomes in Invasive Breast Cancer.
Q26859804	Epithelial-mesenchymal plasticity in carcinoma metastasis
Q26824386	Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance
Q35029475	Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression
Q39085731	Epithelial-mesenchymal transition in tumor metastasis
Q34880376	Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients.
Q57109975	Epithelial-to-mesenchymal transition and cancer stem cells contribute to breast cancer heterogeneity
Q37200831	ErbB3 downregulation enhances luminal breast tumor response to antiestrogens
Q37524229	Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal
Q34268870	Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Q38883472	Establishment of an mKate2-Expressing Cell Line for Non-Invasive Real-Time Breast Cancer In Vivo Imaging
Q52730161	Establishment of two basal-like breast cancer cell lines with extremely low tumorigenicity from Taiwanese premenopausal women.
Q45073978	Estrogen induces c-Kit and an aggressive phenotype in a model of invasive lobular breast cancer
Q55687390	Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression.
Q33848950	Estrogen receptor-α, progesterone receptor, and c-erbB/HER-family receptor mRNA detection and phenotype analysis in spontaneous canine models of breast cancer
Q64054816	Evaluating cell lines as models for metastatic breast cancer through integrative analysis of genomic data
Q35503492	Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value
Q35979379	Exometabolom analysis of breast cancer cell lines: Metabolic signature
Q34820412	Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways
Q28066481	Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancer
Q36924443	Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.
Q42510313	Expression of calretinin in high-grade hormone receptor-negative invasive breast carcinomas: correlation with histological and molecular subtypes.
Q37625774	Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype.
Q36042570	Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential
Q38708750	Expression of tripartite motif-containing protein 28 in primary breast carcinoma predicts metastasis and is involved in the stemness, chemoresistance, and tumor growth
Q48141048	Expression patterns of claudins in patients with triple-negative breast cancer are associated with nodal metastasis and worse outcome
Q21195201	Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers
Q36204224	FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo
Q37689013	FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort
Q36698254	FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer.
Q44076458	Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer
Q35182598	Fibromatosis-like metaplastic carcinoma of the breast has a claudin-low immunohistochemical phenotype
Q34310997	Field cancerization in mammary carcinogenesis - Implications for prevention and treatment of breast cancer
Q36496096	Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance
Q26861636	Functional Role of the microRNA-200 Family in Breast Morphogenesis and Neoplasia
Q52714523	Functional and genomic characterization of a xenograft model system for the study of metastasis in triple-negative breast cancer.
Q37457902	Functional and prognostic significance of long non-coding RNA MALAT1 as a metastasis driver in ER negative lymph node negative breast cancer
Q50790658	Functional characterization of selective exosite-binding inhibitors of matrix metalloproteinase-13 (MMP-13) - experimental validation in human breast and colon cancer.
Q38335759	Functional roles of alternative splicing factors in human disease
Q35980816	G Protein Coupled Receptor Kinase 3 Regulates Breast Cancer Migration, Invasion, and Metastasis
Q35858016	G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer
Q64117140	GALNT3 Maintains the Epithelial State in Trophoblast Stem Cells
Q33761830	GD2 expression in breast cancer.
Q89457584	GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells
Q34704073	GOBO: gene expression-based outcome for breast cancer online
Q89997351	GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer
Q91980872	Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
Q35091690	Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity
Q36245556	Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients.
Q35551926	Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features
Q37528475	Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival
Q37958156	Gene expression profiling in breast cancer: classification, prognostication, and prediction
Q37169835	Gene expression profiling: changing face of breast cancer classification and management
Q41136273	Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast
Q35314135	Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response
Q40274876	Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer.
Q35683564	Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor.
Q38862963	Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset
Q92541740	Genetic Variation in CCL5 Signaling Genes and Triple Negative Breast Cancer: Susceptibility and Prognosis Implications
Q91890943	Genetic determinants of the molecular portraits of epithelial cancers
Q36846498	Genetic susceptibility to triple-negative breast cancer
Q33720872	Genome organizing function of SATB1 in tumor progression
Q36289944	Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant
Q34577891	Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer.
Q35079683	Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity
Q54481772	Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations.
Q34192343	Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse.
Q58574264	Genomic analysis of racial differences in triple negative breast cancer
Q36753689	Genomic and phenotypic profiles of two Brazilian breast cancer cell lines derived from primary human tumors
Q47156532	Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast
Q42486311	Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer
Q53085136	Genomic profiling of histological special types of breast cancer.
Q89267498	Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma
Q37120418	Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.
Q35694382	Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer
Q39319266	Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes
Q91968762	Global gene expression profile in canine mammary carcinomas
Q59795540	Global transcriptional analysis identifies a novel role for SOX4 in tumor-induced angiogenesis
Q37596851	Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target
Q37014479	Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer.
Q41411741	Glycoproteins in Claudin-Low Breast Cancer Cell Lines Have a Unique Expression Profile.
Q35285329	Growth and metastatic behavior of molecularly well-characterized human breast cancer cell lines in mice
Q28085413	HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer
Q38925408	Hereditary breast and ovarian cancer: new genes in confined pathways
Q35551911	Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.
Q35802450	Heterogeneity between triple negative breast cancer cells due to differential activation of Wnt and PI3K/AKT pathways
Q92934298	Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset
Q42942060	Heterogeneity in breast cancer
Q37956043	Heterogeneity of breast cancer: etiology and clinical relevance
Q52684723	High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer.
Q37573642	High-throughput gene expression and mutation profiling: current methods and future perspectives.
Q53241145	Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma.
Q48218331	Histological subtypes of mouse mammary tumors reveal conserved relationships to human cancers
Q34616569	Histological, molecular and functional subtypes of breast cancers
Q41664067	Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises
Q34119025	Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures
Q99408079	Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer
Q28077637	Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women
Q36551617	Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?
Q36473360	Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors
Q38659248	ICRP Publication 131: Stem Cell Biology with Respect to Carcinogenesis Aspects of Radiological Protection
Q38894487	ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotype
Q94588123	IGF1R constitutive activation expands luminal progenitors and influences lineage differentiation during breast tumorigenesis
Q39259470	IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients
Q55268231	IMP3 Stabilization of WNT5B mRNA Facilitates TAZ Activation in Breast Cancer.
Q36714784	ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models
Q36232146	Identification and evaluation of network modules for the prognosis of basal-like breast cancer
Q33874621	Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes
Q33975444	Identification of a novel luminal molecular subtype of breast cancer
Q33645711	Identification of a stable molecular signature in mammary tumor endothelial cells that persists in vitro
Q90480579	Identification of candidate RNA signatures in triple-negative breast cancer by the construction of a competing endogenous RNA network with integrative analyses of Gene Expression Omnibus and The Cancer Genome Atlas data
Q38875037	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis.
Q29617680	Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Q36041569	Identification of intrinsic imaging phenotypes for breast cancer tumors: preliminary associations with gene expression profiles
Q57490070	Identification of miR-200c and miR141-Mediated lncRNA-mRNA Crosstalks in Muscle-Invasive Bladder Cancer Subtypes
Q42505597	Identification of quiescent and spatially restricted mammary stem cells that are hormone responsive.
Q34972623	Identification of the YES1 Kinase as a Therapeutic Target in Basal-Like Breast Cancers
Q26851827	Identifying and targeting tumor-initiating cells in the treatment of breast cancer
Q60915327	Identifying genes with tri-modal association with survival and tumor grade in cancer patients
Q30965908	Identifying network biomarkers based on protein-protein interactions and expression data
Q38241276	Illuminating breast cancer invasion: diverse roles for cell-cell interactions
Q55032160	Immune Landscape of Breast Cancers.
Q33761491	Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis
Q64999098	Immunoexpression of claudins 4 and 7 among invasive breast carcinoma subtypes: A large diagnostic study using tissue microarray.
Q33684982	Immunoexpression of lactoferrin in triple-negative breast cancer patients: A proposal to select a less aggressive subgroup
Q92625382	Immunohistochemical Expression of Vimentin in Invasive Breast Carcinoma and Its Correlation with Clinicopathological Parameters
Q36778827	Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects
Q90402359	Impact of chemotherapy on the expression of claudins and cadherins in invasive breast cancer
Q33739253	Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study
Q36935015	Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancer
Q38862416	Impairment of human neural crest cell migration by prolonged exposure to interferon-beta.
Q37872301	Implications of genomic instability in the diagnosis and treatment of breast cancer
Q26799987	Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis
Q34720254	Improving breast cancer survival analysis through competition-based multidimensional modeling
Q34764103	In vitro analysis of breast cancer cell line tumourspheres and primary human breast epithelia mammospheres demonstrates inter- and intrasphere heterogeneity.
Q34564798	Inactivation of RARβ inhibits Wnt1-induced mammary tumorigenesis by suppressing epithelial-mesenchymal transitions.
Q33727273	Increased macroH2A1.1 expression correlates with poor survival of triple-negative breast cancer patients
Q36545999	Increased metastasis with loss of E2F2 in Myc-driven tumors
Q37651843	Induced p53 loss in mouse luminal cells causes clonal expansion and development of mammary tumours.
Q37588310	Induction of HOXA9 expression in three-dimensional organotypic culture of the Claudin-low breast cancer cells
Q36545233	Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells
Q47137189	Induction of a novel isoform of the lncRNA HOTAIR in Claudin-low breast cancer cells attached to extracellular matrix
Q30571243	Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent
Q36732552	Inflammation and Hras signaling control epithelial-mesenchymal transition during skin tumor progression.
Q39315724	Information theoretic sub-network mining characterizes breast cancer subtypes in terms of cancer core mechanisms
Q41612992	Inhibition of FAK kinase activity preferentially targets cancer stem cells
Q42101498	Inhibition of proliferation and migration of luminal and claudin-low breast cancer cells by PDGFR inhibitors
Q27853151	Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.
Q37642845	Ink4a/Arf(-/-) and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f(-) quiescent cells.
Q35962810	Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer
Q92092227	Integrated analyses of murine breast cancer models reveal critical parallels with human disease
Q58797844	Integrative analysis of the inter-tumoral heterogeneity of triple-negative breast cancer
Q37605645	Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets.
Q36754194	Integrative physical oncology
Q41471118	Interaction of glycosphingolipids GD3 and GD2 with growth factor receptors maintains breast cancer stem cell phenotype
Q36989015	Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer.
Q37234841	Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis
Q92989981	Interrogation of Phenotypic Plasticity between Epithelial and Mesenchymal States in Breast Cancer
Q35203271	Intra-tumour signalling entropy determines clinical outcome in breast and lung cancer
Q38709186	Intratumoral bidirectional transitions between epithelial and mesenchymal cells in triple-negative breast cancer.
Q42506362	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.
Q38222834	Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer
Q58053534	Intrinsic cancer subtypes-next steps into personalized medicine
Q55078504	Intrinsic subtypes and bladder cancer metastasis.
Q37612632	Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
Q35576242	Invasive Breast Cancer: Recognition of Molecular Subtypes
Q35025646	Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics
Q34476337	Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
Q36490203	Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?
Q47697280	Isolation of Breast cancer CTCs with multitargeted buoyant immunomicrobubbles
Q36245402	JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer.
Q52347720	KIBRA (WWC1) Is a Metastasis Suppressor Gene Affected by Chromosome 5q Loss in Triple-Negative Breast Cancer.
Q64445673	KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals
Q24296484	KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer
Q35964972	Kaiso depletion attenuates transforming growth factor-β signaling and metastatic activity of triple-negative breast cancer cells
Q90010879	LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer
Q37055054	Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer
Q36741528	Latest research progress in the correlation between baicalein and breast cancer invasion and metastasis
Q36058024	Lectin chromatography/mass spectrometry discovery workflow identifies putative biomarkers of aggressive breast cancers
Q38213543	Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy
Q52723870	Leukotriene Receptor Antagonists Inhibit Mitogenic Activity in Triple Negative Breast Cancer Cells
Q92442312	Lipid Droplets Define a Sub-Population of Breast Cancer Stem Cells
Q21132473	Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer
Q34556770	Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer.
Q35995591	Loss of Panx1 Impairs Mammary Gland Development at Lactation: Implications for Breast Tumorigenesis
Q37549104	Loss of WISP2/CCN5 in estrogen-dependent MCF7 human breast cancer cells promotes a stem-like cell phenotype
Q34133391	Loss of breast epithelial marker hCLCA2 promotes epithelial-to-mesenchymal transition and indicates higher risk of metastasis
Q98771231	Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients
Q37299331	Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells
Q58774122	Low serum gastrin associated with ER breast cancer development via inactivation of CCKBR/ERK/P65 signaling
Q36513217	Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco
Q35020412	Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy
Q41667225	Lunatic Fringe and p53 Cooperatively Suppress Mesenchymal Stem-Like Breast Cancer
Q36702175	Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer.
Q34961989	MAP3K4/CBP-regulated H2B acetylation controls epithelial-mesenchymal transition in trophoblast stem cells
Q48231466	MCL-1 is a prognostic indicator and drug target in breast cancer
Q33657478	MMTV-Espl1 transgenic mice develop aneuploid, estrogen receptor alpha (ERα)-positive mammary adenocarcinomas
Q38135451	MR imaging features of triple-negative breast cancers
Q49272521	MUC1 induces M2 type macrophage influx during postpartum mammary gland involution and triggers breast cancer
Q37014197	MYC Is a Crucial Mediator of TGFβ-Induced Invasion in Basal Breast Cancer
Q92669420	MYC regulates fatty acid metabolism through a multigenic program in claudin-low triple negative breast cancer
Q90083168	Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes
Q35800693	Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs.
Q35779391	Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch
Q47147401	Mammalian sterile 20-like kinase 1 expression and its prognostic significance in patients with breast cancer.
Q57112976	Mammary Stem Cells and Breast Cancer Stem Cells: Molecular Connections and Clinical Implications
Q26830779	Mammary gland stem cells: more puzzles than explanations
Q27003345	Mammary stem cells and the differentiation hierarchy: current status and perspectives
Q89700474	Mammary stem cells: angels or demons in mammary gland?
Q35661710	Mammary tumors that become independent of the type I insulin-like growth factor receptor express elevated levels of platelet-derived growth factor receptors
Q35155460	Management options in triple-negative breast cancer
Q37190619	Manganese Superoxide Dismutase Expression Regulates the Switch Between an Epithelial and a Mesenchymal-Like Phenotype in Breast Carcinoma
Q37734011	Manganese superoxide dismutase is a promising target for enhancing chemosensitivity of basal-like breast carcinoma.
Q35612277	Manic fringe promotes a claudin-low breast cancer phenotype through notch-mediated PIK3CG induction.
Q52805550	Matrix metalloproteinase-9 (MMP9) is involved in the TNF-α-induced fusion of human M13SV1-Cre breast epithelial cells and human MDA-MB-435-pFDR1 cancer cells.
Q28084024	Mechanisms involved in breast cancer liver metastasis
Q92826406	Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge
Q47176980	Mesenchymal phenotype of circulating tumor cells is associated with distant metastasis in breast cancer patients
Q36472268	Mesenchymal traits are selected along with stem features in breast cancer cells grown as mammospheres
Q27316936	Met kinetic signature derived from the response to HGF/SF in a cellular model predicts breast cancer patient survival
Q36747465	Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer
Q37363521	Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use
Q38696301	Metabolic reprogramming underlies metastatic potential in an obesity-responsive murine model of metastatic triple negative breast cancer
Q34283295	Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype
Q42513445	Metalloprotease-dependent activation of EGFR modulates CD44+/CD24- populations in triple negative breast cancer cells through the MEK/ERK pathway.
Q37620891	Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer
Q37352137	Metalloproteinase-disintegrin ADAM12 is associated with a breast tumor-initiating cell phenotype.
Q38359372	Metaplastic breast cancer: clinical overview and molecular aberrations for potential targeted therapy
Q35911470	Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected]. .
Q42467629	Metaplastic carcinoma show different expression pattern of YAP compared to triple-negative breast cancer.
Q38641240	Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies
Q38790790	Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer.
Q36143153	Methylation profile of triple-negative breast carcinomas
Q37190321	MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer
Q35000619	MiR-183/-96/-182 cluster is up-regulated in most breast cancers and increases cell proliferation and migration
Q39095883	MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways.
Q30539640	MicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition
Q34462262	MicroRNA-200 family modulation in distinct breast cancer phenotypes
Q37044582	MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11.
Q36641467	MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion.
Q37746031	MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
Q34299430	MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells.
Q26862716	MicroRNAs and triple negative breast cancer
Q26823360	MicroRNAs in breast cancer initiation and progression
Q35558070	Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction
Q38848773	Microelectrode bioimpedance analysis distinguishes basal and claudin-low subtypes of triple negative breast cancer cells
Q39509229	Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification.
Q26748850	Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells
Q36790655	Mitochondrial ATAD3A combines with GRP78 to regulate the WASF3 metastasis-promoting protein
Q41260173	Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo phenotype and patient prognosis
Q61816625	Modeling Tumor Phenotypes In Vitro with Three-Dimensional Bioprinting
Q39248988	Modeling and characterization of inflammatory breast cancer emboli grown in vitro
Q64109139	Modeling differentiation-state transitions linked to therapeutic escape in triple-negative breast cancer
Q38078338	Molecular alterations in metaplastic breast carcinoma
Q38133084	Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine
Q39399933	Molecular and clinicopathological markers of prognosis in breast cancer.
Q35684581	Molecular basis of triple negative breast cancer and implications for therapy
Q34476551	Molecular characterisation of cell line models for triple-negative breast cancers
Q35530143	Molecular characterization and targeted therapeutic approaches in breast cancer
Q36630430	Molecular characterization of basal-like and non-basal-like triple-negative breast cancer
Q33750808	Molecular characterization of breast cancer cell lines by clinical immunohistochemical markers.
Q38216166	Molecular classification of breast cancer
Q42451288	Molecular classification of metaplastic carcinoma using surrogate immunohistochemical staining.
Q46131870	Molecular classification of triple-negative tumors
Q35928897	Molecular portrait of breast cancer in China reveals comprehensive transcriptomic likeness to Caucasian breast cancer and low prevalence of luminal A subtype.
Q36099968	Molecular portraits revealing the heterogeneity of breast tumor subtypes defined using immunohistochemistry markers
Q37302484	Molecular profiling for breast cancer: a comprehensive review
Q54403385	Molecular prognostic and predictive markers of breast cancer treatment
Q91973648	Molecular stratification within triple-negative breast cancer subtypes
Q38061108	Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.
Q47374603	Molecular subtyping of breast cancer improves identification of both high and low risk patients.
Q38184381	Molecular tests as prognostic factors in breast cancer
Q38998265	Mouse Models of Breast Cancer Share Amplification and Deletion Events with Human Breast Cancer
Q42770299	Mouse models and anti-HER2 therapies
Q59791901	Moving Breast Cancer Therapy up a Notch
Q92730905	Multi-Omics Characterization of the Spontaneous Mesenchymal-Epithelial Transition in the PMC42 Breast Cancer Cell Lines
Q42514809	Multidimensional phenotyping of breast cancer cell lines to guide preclinical research
Q34123261	Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin
Q36165196	Multipotent luminal mammary cancer stem cells model tumor heterogeneity
Q35206221	Murine mammary tumor cells with a claudin-low genotype
Q37066581	Murine microenvironment metaprofiles associate with human cancer etiology and intrinsic subtypes
Q36219957	Mutant PIK3CA Induces EMT in a Cell Type Specific Manner
Q37143534	Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies
Q34654793	Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences
Q34248585	Myc is required for β-catenin-mediated mammary stem cell amplification and tumorigenesis
Q59128928	NMT1 inhibition modulates breast cancer progression through stress-triggered JNK pathway
Q89910309	NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer
Q91587906	Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin
Q55633505	Nanoparticle-Mediated Therapeutic Agent Delivery for Treating Metastatic Breast Cancer-Challenges and Opportunities.
Q55043805	Natural Products for the Management and Prevention of Breast Cancer.
Q58795373	Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer
Q50093673	NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer
Q91941572	Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer
Q37568043	Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation.
Q49900625	Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer
Q38074564	New biological insights on the link between radiation exposure and breast cancer risk
Q37094064	New generation of breast cancer clinical trials implementing molecular profiling
Q42837223	New light on Smac mimetics and breast cancer
Q34634272	Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity
Q89597721	Non-Coding RNAs as Regulators and Markers for Targeting of Breast Cancer and Cancer Stem Cells
Q89574633	Normal Breast-Derived Epithelial Cells with Luminal and Intrinsic Subtype-Enriched Gene Expression Document Interindividual Differences in Their Differentiation Cascade
Q44063727	Normal and cancerous mammary stem cells evade interferon-induced constraint through the miR-199a-LCOR axis
Q36397832	Normal cell phenotypes of breast epithelial cells provide the foundation of a breast cancer taxonomy
Q58544241	Notch and Wnt Dysregulation and Its Relevance for Breast Cancer and Tumor Initiation
Q55429263	Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
Q34285190	Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function.
Q33887682	Novel therapeutic strategies in the treatment of triple-negative breast cancer
Q92541751	OSbrca: A Web Server for Breast Cancer Prognostic Biomarker Investigation With Massive Data From Tens of Cohorts
Q58765189	Obesity promotes the expansion of metastasis-initiating cells in breast cancer
Q39355041	Oncogenic PI3K mutations lead to NF-κB-dependent cytokine expression following growth factor deprivation
Q38215948	Oncogenic roles of EMT-inducing transcription factors
Q51069613	Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer.
Q36047389	Osteopontin regulates proliferation, apoptosis, and migration of murine claudin-low mammary tumor cells
Q89666620	Outcomes after Treatment of Metaplastic Versus Other Breast Cancer Subtypes
Q37364604	Outcomes of her2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients
Q90044977	Overexpression and alternative splicing of NF-YA in breast cancer
Q38578970	Overview of Genetically Engineered Mouse Models of Breast Cancer Used in Translational Biology and Drug Development
Q36784065	Overview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes
Q38888783	Oxidative stress shapes breast cancer phenotype through chronic activation of ATM-dependent signaling
Q36147185	PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer
Q34433549	PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
Q33883406	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).
Q39189607	PELO negatively regulates HER receptor signalling and metastasis
Q35610581	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer
Q91815720	Pannexin1 Is Associated with Enhanced Epithelial-To-Mesenchymal Transition in Human Patient Breast Cancer Tissues and in Breast Cancer Cell Lines
Q55007506	Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model.
Q36798949	Paracrine Wnt signaling both promotes and inhibits human breast tumor growth
Q41379546	PathAct: a novel method for pathway analysis using gene expression profiles
Q88959868	Patient Similarity Networks for Precision Medicine
Q36903447	Patient-derived breast tumor xenografts facilitating personalized cancer therapy
Q39057246	Patient-derived xenograft (PDX) models in basic and translational breast cancer research.
Q27026531	Patient-derived xenograft models of breast cancer and their predictive power
Q34037747	Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century
Q36526547	Patterns in target-directed breast cancer research
Q33731365	Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells
Q42505998	Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers.
Q64934294	Personalized medicine in breast cancer: pharmacogenomics approaches.
Q43828188	Personalized medicine in cancer: where are we today?
Q38196466	Personalized therapy for breast cancer
Q36328010	Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer
Q39029043	Pharmacological and immunological targeting of tumor mesenchymalization
Q48266858	Phenotypic characteristics of colorectal cancer in BRCA1/2 mutation carriers.
Q35102562	Pluripotent stem cell miRNAs and metastasis in invasive breast cancer
Q90312093	Potential Role of MSC/Cancer Cell Fusion and EMT for Breast Cancer Stem Cell Formation
Q41134799	Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer
Q59812268	Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis
Q33719480	Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer.
Q100764047	Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
Q55010484	Precision Medicine for Breast Cancer: The Paths to Truly Individualized Diagnosis and Treatment.
Q57105411	Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer
Q47406496	Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy
Q33809114	Precision medicine in breast cancer: reality or utopia?
Q38790859	Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor
Q37187379	Predicting drug responsiveness in human cancers using genetically engineered mice.
Q34354538	Predicting response and survival in chemotherapy-treated triple-negative breast cancer.
Q52714651	Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67.
Q38687963	Predictive factors on outcomes in metaplastic breast cancer.
Q42454757	Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures
Q48573972	Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis
Q36449295	Profiling the immune stromal interface in breast cancer and its potential for clinical impact
Q33916814	Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer
Q33646271	Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers
Q49868941	Prognostic Significance of Low Claudin3 Expression in Luminal Breast Cancers
Q91739070	Prognostic phenotypic classification for canine mammary tumors
Q64094448	Prognostic role of Tif1γ expression and circulating tumor cells in patients with breast cancer
Q57298068	Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer
Q35180291	Prognostic stromal gene signatures in breast cancer.
Q54519817	Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer.
Q37200485	Prognostic value of the trichorhinophalangeal syndrome-1 (TRPS-1), a GATA family transcription factor, in early-stage breast cancer
Q33555787	Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas
Q39546203	Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs
Q91291806	Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer
Q38715089	Promotion of invasion by mutant RAS is dependent on activation of the WASF3 metastasis promoter gene.
Q37620729	Prostate apoptosis response-4 mediates TGF-β-induced epithelial-to-mesenchymal transition
Q93087257	Protein C receptor is a therapeutic stem cell target in a distinct group of breast cancers
Q47261659	Protein biomarkers for subtyping breast cancer and implications for future research.
Q36289925	Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice
Q58720701	Proteomic analysis identifies highly expressed plasma membrane proteins for detection and therapeutic targeting of specific breast cancer subtypes
Q37696322	Pubertal and adult windows of susceptibility to a high animal fat diet in Trp53-null mammary tumorigenesis
Q37685858	Pubertal bisphenol A exposure alters murine mammary stem cell function leading to early neoplasia in regenerated glands
Q27340972	Py2T murine breast cancer cells, a versatile model of TGFβ-induced EMT in vitro and in vivo
Q90749231	Pyridine-Containing Macrocycles Display MMP-2/9 Inhibitory Activity and Distinct Effects on Migration and Invasion of 2D and 3D Breast Cancer Models
Q64112956	Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes
Q37395680	RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation
Q36629504	RKIP regulates CCL5 expression to inhibit breast cancer invasion and metastasis by controlling macrophage infiltration.
Q35922859	Race-associated biological differences among Luminal A breast tumors
Q24620175	Radiation acts on the microenvironment to affect breast carcinogenesis by distinct mechanisms that decrease cancer latency and affect tumor type
Q37244377	Radiation-induced gene signature predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer patients
Q42446501	Raf kinase inhibitory protein role in the molecular subtyping of breast cancer
Q34005143	Rare breast cancer subtypes: histological, molecular, and clinical peculiarities
Q91891797	Re-definition of claudin-low as a breast cancer phenotype
Q33618841	Re-expression of miR-200c suppresses proliferation, colony formation and in vivo tumor growth of murine claudin-low mammary tumor cells.
Q55353691	Recent Advances in the Treatment of Breast Cancer.
Q64100317	Recent advances in understanding tumor stroma-mediated chemoresistance in breast cancer
Q38946859	Recent progress with next-generation biomarkers in muscle-invasive bladder cancer.
Q92818881	Refinement of breast cancer molecular classification by miRNA expression profiles
Q89870493	Regulation and New Treatment Strategies in Breast Cancer
Q92316377	Regulation of Immunity in Breast Cancer
Q38851695	Regulation of stem cells-related signaling pathways in response to doxorubicin treatment in Hs578T triple-negative breast cancer cells.
Q28534173	Regulation of the Epithelial-Mesenchymal Transition by Claudin-3 and Claudin-4
Q33995723	Remodeling of purinergic receptor-mediated Ca2+ signaling as a consequence of EGF-induced epithelial-mesenchymal transition in breast cancer cells
Q36342182	Reproductive history and breast cancer risk.
Q90203353	Research-based PAM50 signature and long-term breast cancer survival
Q33659361	Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population
Q36383626	Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy
Q90610564	Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
Q90152296	Resveratrol Modifies Lipid Composition of Two Cancer Cell Lines
Q42378446	Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes
Q42282489	Revisiting the impact of age and molecular subtype on overall survival after radiotherapy in breast cancer patients
Q54546191	Risk factors for HR- and HER2-defined breast cancer in Slovenian postmenopausal women.
Q92749855	Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26
Q92155709	Role of Claudin Proteins in Regulating Cancer Stem Cells and Chemoresistance-Potential Implication in Disease Prognosis and Therapy
Q37690034	Role of HGF in epithelial-stromal cell interactions during progression from benign breast disease to ductal carcinoma in situ
Q35535296	Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation
Q36677690	Role of microRNAs in breast cancer
Q42511518	Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression
Q36640358	S100A8/A9 is associated with estrogen receptor loss in breast cancer
Q37447994	SIK2 Restricts Autophagic Flux To Support Triple-Negative Breast Cancer Survival
Q64882163	SMYD3 promotes the epithelial-mesenchymal transition in breast cancer.
Q34850997	SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model
Q58709738	SOX4 can redirect TGF-β-mediated SMAD3-transcriptional output in a context-dependent manner to promote tumorigenesis
Q91943174	SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression
Q38988872	STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer
Q37036337	SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling
Q36191982	Screening and characterization of novel specific peptides targeting MDA-MB-231 claudin-low breast carcinoma by computer-aided phage display methodologies
Q44094790	Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial
Q91854833	Selective Effects of Thioridazine on Self-Renewal of Basal-Like Breast Cancer Cells
Q35845827	Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
Q38777346	Sensitizing basal-like breast cancer to chemotherapy using nanoparticles conjugated with interference peptide.
Q47867377	Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells
Q38398043	Shotgun proteomics of archival triple-negative breast cancer samples
Q45058372	Should we treat minimal breast cancer lesions?
Q35213019	Signaling mechanisms of the epithelial-mesenchymal transition
Q35000293	Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway
Q89985480	Silver nanoparticles selectively treat triple-negative breast cancer cells without affecting non-malignant breast epithelial cells in vitro and in vivo
Q33889288	Simultaneous siRNA targeting of Src and downstream signaling molecules inhibit tumor formation and metastasis of a human model breast cancer cell line
Q98718297	Single-cell RNA-sequencing reveals distinct patterns of cell state heterogeneity in mouse models of breast cancer
Q58799648	Somatic loss of WWOX is associated with TP53 perturbation in basal-like breast cancer
Q27320285	Sox10 Regulates Stem/Progenitor and Mesenchymal Cell States in Mammary Epithelial Cells
Q52575440	Specific breast cancer prognosis-subtype distinctions based on DNA methylation patterns.
Q90114938	Specific chromatin landscapes and transcription factors couple breast cancer subtype with metastatic relapse to lung or brain
Q91713420	Sphingosine Kinase 1 in Breast Cancer-A New Molecular Marker and a Therapy Target
Q36436933	Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors
Q31132069	Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer
Q34774884	Standard of care and promising new agents for triple negative metastatic breast cancer
Q47151800	Statistical significance for hierarchical clustering.
Q42972655	Stratifying triple-negative breast cancer: which definition(s) to use?
Q47768899	Suppression of MAPK signaling in BRAF-activated PTEN-deficient melanoma by blocking β-catenin signaling in cancer-associated fibroblasts
Q21135222	Suppression of breast tumor growth and metastasis by an engineered transcription factor
Q36353410	Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34⁺ cells in a xenograft model
Q64325058	Survival Study of Triple-Negative and Non-Triple-Negative Breast Cancer in a Brazilian Cohort
Q24624489	Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
Q34049023	Systematic analysis of metastasis-associated genes identifies miR-17-5p as a metastatic suppressor of basal-like breast cancer.
Q37331472	Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer
Q34576377	Systems biology and genomics of breast cancer
Q36145430	TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer
Q33954557	TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
Q27853147	TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
Q61804904	TBL1 is required for the mesenchymal phenotype of transformed breast cancer cells
Q42512528	TGFβ induces the formation of tumour-initiating cells in claudinlow breast cancer
Q39368430	TIP60 inhibits metastasis by ablating DNMT1-SNAIL2-driven epithelial-mesenchymal transition program.
Q93075081	TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities
Q36148592	TP53 mutation, epithelial-mesenchymal transition, and stemlike features in breast cancer subtypes
Q42510422	TRPC1 is a differential regulator of hypoxia-mediated events and Akt signalling in PTEN-deficient breast cancer cells
Q37697038	TRPC1-STIM1 activation modulates transforming growth factor β-induced epithelial-to-mesenchymal transition
Q99207626	TRPV6 calcium channel directs homeostasis of the mammary epithelial sheets and controls epithelial mesenchymal transition
Q36476219	Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer
Q36144913	Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer
Q37190825	Targeted therapy for breast cancer prevention
Q38009760	Targeted therapy for triple-negative breast cancer: where are we?
Q39456790	Targeting Androgen/Estrogen Receptors Crosstalk in Cancer
Q57107358	Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance
Q38209586	Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer
Q33631501	Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.
Q35174128	Targeting a cell state common to triple-negative breast cancers
Q47385983	Targeting bromodomain and extraterminal proteins in breast cancer
Q38836110	Targeting the Breast Cancer Kinome
Q39339106	Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field
Q36790763	Targeting the WASF3-CYFIP1 Complex Using Stapled Peptides Suppresses Cancer Cell Invasion
Q42364449	Targeting the androgen receptor in triple-negative breast cancer: current perspectives
Q36245380	Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
Q38295108	The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer
Q39071403	The Cellular Origin and Evolution of Breast Cancer
Q35687706	The Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast Carcinomas
Q91715241	The Detection and Morphological Analysis of Circulating Tumor and Host Cells in Breast Cancer Xenograft Models
Q30978083	The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.
Q42516196	The Epithelial-to-Mesenchymal Transition in Breast Cancer: Focus on Basal-Like Carcinomas
Q95267155	The Expression and Prognostic Significance of Claudin-8 and Androgen Receptor in Breast Cancer
Q34495216	The FGF/FGFR axis as a therapeutic target in breast cancer
Q42371555	The H3K27me3-demethylase KDM6A is suppressed in breast cancer stem-like cells, and enables the resolution of bivalency during the mesenchymal-epithelial transition
Q89286757	The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome
Q92859442	The MMTV-Wnt1 murine model produces two phenotypically distinct subtypes of mammary tumors with unique therapeutic responses to an EGFR inhibitor
Q90080264	The Molecular Mechanism of Epithelial-Mesenchymal Transition for Breast Carcinogenesis
Q64066030	The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines
Q36947310	The RUNX2 Transcription Factor Negatively Regulates SIRT6 Expression to Alter Glucose Metabolism in Breast Cancer Cells
Q57817312	The SCRIB Paralog LANO/LRRC1 Regulates Breast Cancer Stem Cell Fate through WNT/β-Catenin Signaling
Q39453298	The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions
Q36109766	The T box transcription factor TBX2 promotes epithelial-mesenchymal transition and invasion of normal and malignant breast epithelial cells
Q36580632	The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl
Q38890318	The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness
Q38757069	The WASF3-NCKAP1-CYFIP1 Complex Is Essential for Breast Cancer Metastasis
Q47372771	The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes
Q34086632	The breast cancer genome--a key for better oncology
Q27317001	The calcium pump plasma membrane Ca(2+)-ATPase 2 (PMCA2) regulates breast cancer cell proliferation and sensitivity to doxorubicin.
Q36336601	The changing role of ER in endocrine resistance
Q47167746	The crossroads of breast cancer progression: insights into the modulation of major signaling pathways
Q47236781	The depalmitoylase APT1 directs the asymmetric partitioning of Notch and Wnt signaling during cell division
Q36507087	The dual function of PRMT1 in modulating epithelial-mesenchymal transition and cellular senescence in breast cancer cells through regulation of ZEB1
Q36903188	The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarker
Q44770771	The exon 38-containing ARHGEF11 splice isoform is differentially expressed and is required for migration and growth in invasive breast cancer cells
Q34472128	The expression and clinical significance of ribophorin II (RPN2) in human breast cancer
Q26775232	The fate of chemoresistance in triple negative breast cancer (TNBC)
Q36098052	The forkhead box transcription factor FOXC1 promotes breast cancer invasion by inducing matrix metalloprotease 7 (MMP7) expression.
Q36924454	The gene expression landscape of breast cancer is shaped by tumor protein p53 status and epithelial-mesenchymal transition
Q37691054	The genomic map of breast cancer: which roads lead to better targeted therapies?
Q26740373	The hedgehog pathway in triple-negative breast cancer
Q103806134	The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer
Q33660069	The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.
Q38208007	The involvement of JAK-STAT3 in cell motility, invasion, and metastasis
Q35032523	The landscape of candidate driver genes differs between male and female breast cancer
Q34258373	The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers
Q38026421	The malignant social network: cell-cell adhesion and communication in cancer stem cells
Q34396558	The mammary cellular hierarchy and breast cancer.
Q36525461	The origin of breast tumor heterogeneity
Q91239720	The pleiotropic effects of TNFα in breast cancer subtypes is regulated by TNFAIP3/A20
Q37376414	The prognostic and predictive value of the lymphocyte to monocyte ratio in luminal-type breast cancer patients treated with CEF chemotherapy
Q40714796	The prognostic impact of age in different molecular subtypes of breast cancer
Q48002827	The prognostic role of claudins in head and neck squamous cell carcinomas
Q46842412	The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer
Q27005952	The promise of multi-omics and clinical data integration to identify and target personalized healthcare approaches in autism spectrum disorders
Q27320721	The proteomic landscape of triple-negative breast cancer
Q35657873	The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium
Q38483125	The relevance of EMT in breast cancer metastasis: Correlation or causality?
Q37118399	The relevance of the TGF-β Paradox to EMT-MET programs
Q38927656	The role of claudins in cancer metastasis
Q37123982	The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective
Q35122705	The role of lipolysis stimulated lipoprotein receptor in breast cancer and directing breast cancer cell behavior
Q96222254	The testis protein ZNF165 is a SMAD3 cofactor that coordinates oncogenic TGFβ signaling in triple-negative breast cancer
Q90484944	The therapeutic response of ER+/HER2- breast cancers differs according to the molecular Basal or Luminal subtype
Q28743642	The transcription factors Snail and Slug activate the transforming growth factor-beta signaling pathway in breast cancer
Q55174811	The versatile nature of miR-9/9* in human cancer.
Q47638243	Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer.
Q38084287	Therapeutic targets in triple negative breast cancer
Q38424397	Therapies for triple negative breast cancer
Q58763424	TiHo-0906: a new feline mammary cancer cell line with molecular, morphological, and immunocytological characteristics of epithelial to mesenchymal transition
Q61811129	Tight Junction Proteins and Signaling Pathways in Cancer and Inflammation: A Functional Crosstalk
Q36343793	Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases
Q37118065	Tight junction proteins: from barrier to tumorigenesis.
Q37989074	Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?
Q26829478	Tracking the intermediate stages of epithelial-mesenchymal transition in epithelial stem cells and cancer
Q39242906	Transcription factors link mouse WAP-T mammary tumors with human breast cancer
Q64068503	Transcriptional factor six2 promotes the competitive endogenous RNA network between CYP4Z1 and pseudogene CYP4Z2P responsible for maintaining the stemness of breast cancer cells
Q33742688	Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts
Q47134924	Transforming Growth Factor-beta Regulation of Ephrin Type-A Receptor 4 Signaling in Breast Cancer Cellular Migration
Q36081908	Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature
Q37711615	Transposon insertional mutagenesis in mice identifies human breast cancer susceptibility genes and signatures for stratification
Q35934478	Trastuzumab and docetaxel in a preclinical organotypic breast cancer model using tissue slices from mammary fat pad: Translational relevance.
Q47927802	Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer
Q64097271	Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity
Q38007037	Triple negative breast cancer: a brief review of its characteristics and treatment options
Q26783122	Triple negative breast cancer: looking for the missing link between biology and treatments
Q42498742	Triple-Negative Breast Cancer: A Comprehensive Study of Clinical, Histomorphological, and Immunohistochemical Features in Indian Patients
Q90040642	Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness
Q57115890	Triple-negative breast cancer and the potential for targeted therapy
Q35549438	Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes.
Q35692146	Triple-negative breast cancer: adjuvant therapeutic options
Q33915057	Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants
Q36940085	Triple-negative breast cancer: treatment challenges and solutions
Q34269541	Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer
Q36471435	Tumor Cell-Derived Periostin Regulates Cytokines That Maintain Breast Cancer Stem Cells.
Q47146956	Tumor Heterogeneity in Breast Cancer
Q21296683	Tumor angiogenesis: pericytes and maturation are not to be ignored
Q36411711	Tumor characteristics and the clinical outcome of invasive lobular carcinoma compared to infiltrating ductal carcinoma in a Chinese population
Q35624103	Tumor intrinsic subtype is reflected in cancer-adjacent tissue.
Q90748016	Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers
Q35575679	Tumor twitter: cellular communication in the breast cancer stem cell niche
Q36984367	Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer.
Q45073569	Tumor-Suppressor Inactivation of GDF11 Occurs by Precursor Sequestration in Triple-Negative Breast Cancer
Q49494144	Tumor-infiltrating lymphocytes are associated with β-catenin overexpression in breast cancer
Q58799845	Tumor-stroma interactions differentially alter drug sensitivity based on the origin of stromal cells
Q36557847	Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer.
Q33613560	Tumour-initiating capacity is independent of epithelial-mesenchymal transition status in breast cancer cell lines
Q84594497	Two possible mechanisms of epithelial to mesenchymal transition in invasive ductal breast cancer
Q47614178	Ubiquitin-Specific Protease USP6 Regulates the Stability of the c-Jun Protein.
Q43407097	Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets
Q26773472	Understanding the role of the kynurenine pathway in human breast cancer immunobiology
Q52587869	Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
Q36311616	Update on triple-negative breast cancer: prognosis and management strategies
Q47193038	Using gene expression data to direct breast cancer therapy: evidence from a preclinical trial
Q40123917	Variability in DNA Repair Capacity Levels among Molecular Breast Cancer Subtypes: Triple Negative Breast Cancer Shows Lowest Repair
Q92539420	Variational Autoencoders for Cancer Data Integration: Design Principles and Computational Practice
Q35000353	Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3.
Q34034767	Vimentin DNA methylation predicts survival in breast cancer
Q37016288	Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma.
Q37124053	WASF3 provides the conduit to facilitate invasion and metastasis in breast cancer cells through HER2/HER3 signaling
Q37720633	WASF3 regulates miR-200 inactivation by ZEB1 through suppression of KISS1 leading to increased invasiveness in breast cancer cells
Q91948227	WITHDRAWN: Tanshinone IIA-mediated inhibition on miR-125b/STARD13 axis attenuates the stemness and enhances adriamycin sensitivity of breast cancer cells
Q91297679	WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer
Q37721627	WT1 expression in breast cancer disrupts the epithelial/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel
Q50910046	Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component.
Q35883071	Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation
Q39214992	Wnt signaling in triple-negative breast cancer.
Q38529063	ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types
Q47588078	ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells
Q92060237	ZGRF1 Is Associated with Poor Prognosis in Triple-Negative Breast Cancer and Promotes Cancer Stemness Based on Bioinformatics
Q34869169	c-Jun N-terminal kinase 2 (JNK2) enhances cell migration through epidermal growth factor substrate 8 (EPS8).
Q35828457	c-Jun N-terminal kinase 2 prevents luminal cell commitment in normal mammary glands and tumors by inhibiting p53/Notch1 and breast cancer gene 1 expression
Q39093109	c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer.
Q34880881	eEF2K--a new target in breast cancers with combined inactivation of p53 and PTEN
Q38778447	miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer.
Q42493425	miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer
Q28115315	miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer
Q36902949	miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs
Q41252362	microRNA-143/145 loss induces Ras signaling to promote aggressive Pten-deficient basal-like breast cancer
Q33739297	p130Cas/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells
Q42500912	p53 deficiency induces cancer stem cell pool expansion in a mouse model of triple-negative breast tumors
Q34298024	p66ShcA promotes breast cancer plasticity by inducing an epithelial-to-mesenchymal transition
Q61805409	pAKT pathway activation is associated with mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation
Q36070381	ΔNp63α Promotes Breast Cancer Cell Motility through the Selective Activation of Components of the Epithelial-to-Mesenchymal Transition Program
Q37265368	αB-crystallin Expression in Breast Cancer is Associated with Brain Metastasis
Q35930626	β-catenin regulates c-Myc and CDKN1A expression in breast cancer cells.

P6179	Dimensions Publication ID	1032799121
P356	DOI	10.1186/BCR2635
P3181	OpenCitations bibliographic resource ID	548714
P932	PMC publication ID	3096954
P698	PubMed publication ID	20813035
P5875	ResearchGate publication ID	46123527

P50	author	Charles M. Perou	Q30503513
P2093	author name string	Fan C
		He X
		Herschkowitz JI
		Karginova O
		Livasy C
		Parker JS
		Prat A
P2860	cites work	Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome	Q21092905
		Cluster analysis and display of genome-wide expression patterns	Q24644463
		A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes	Q24647928
		The epithelial-mesenchymal transition generates cells with properties of stem cells	Q24650786
		The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas	Q37038629
		Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study	Q39605778
		Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype	Q40012189
		Transcriptome analysis of the normal human mammary cell commitment and differentiation process	Q40075363
		BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants	Q40333192
		Cell-type-specific responses to chemotherapeutics in breast cancer	Q40543849
		Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line	Q40554428
		Refinement of breast cancer classification by molecular characterization of histological special types	Q42440653
		Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers	Q42457867
		Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment.	Q42462949
		BRCA1 dysfunction in sporadic basal-like breast cancer	Q42502209
		The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes	Q42511189
		Establishment of epithelial cell line MDA-MB-157 from metastatic pleural effusion of human breast carcinoma	Q43784825
		Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations	Q47696751
		Mammary development meets cancer genomics.	Q51928701
		Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.	Q51935846
		Phenotypic and functional characterization in vitro of a multipotent epithelial cell present in the normal adult human breast.	Q52184328
		ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome	Q24657877
		Prospective identification of tumorigenic breast cancer cells	Q24683474
		Determination of stromal signatures in breast carcinoma	Q24798099
		DAVID: Database for Annotation, Visualization, and Integrated Discovery	Q27499374
		Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications	Q27860709
		Gene expression profiling predicts clinical outcome of breast cancer	Q27860732
		A gene-expression signature as a predictor of survival in breast cancer	Q27860945
		Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell	Q27861001
		Molecular portraits of human breast tumours	Q28032461
		Systematic variation in gene expression patterns in human cancer cell lines	Q28145747
		Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits	Q28237197
		Identification of selective inhibitors of cancer stem cells by high-throughput screening	Q28255115
		Molecular definition of breast tumor heterogeneity	Q28292256
		Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics	Q28751743
		An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors	Q29615393
		In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells	Q29616498
		Supervised risk predictor of breast cancer based on intrinsic subtypes	Q29617404
		Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy	Q29617584
		''R"--project for statistical computing	Q29618640
		Generation of breast cancer stem cells through epithelial-mesenchymal transition	Q29619717
		Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features	Q29620020
		Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature	Q29622952
		The molecular portraits of breast tumors are conserved across microarray platforms	Q33241398
		Cell-type specific gene expression profiles of leukocytes in human peripheral blood	Q33243638
		EGFR associated expression profiles vary with breast tumor subtype	Q33292502
		Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer.	Q33638070
		Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors	Q33896961
		Two syngeneic cell lines from human breast tissue: the aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst) cell lines	Q34382169
		Concordance among gene-expression-based predictors for breast cancer	Q34555829
		A luminal epithelial stem cell that is a cell of origin for prostate cancer	Q35001982
		Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors	Q35906418
		BRCA1 regulates human mammary stem/progenitor cell fate	Q36446479
		Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy	Q36678657
		The fibromatosis signature defines a robust stromal response in breast carcinoma	Q36841980
P433	issue	5
P407	language of work or name	English	Q1860
P921	main subject	breast cancer	Q128581
P304	page(s)	R68
P577	publication date	2010-01-01
P1433	published in	Breast Cancer Research	Q2208481
P1476	title	Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
P478	volume	12

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

scientific article (publication date: 2010)

Reverse relations